Neurology Central

Novel study reveals ‘fast-acting benefits’ of ketamine for depression

In a study recently published in The American Journal of Psychiatry, a multi-institutional group of researchers have revealed that a nasal spray formulation of ketamine holds promise in the rapid treatment of symptoms of major depression and suicidal thoughts.

In the double-blind, multicenter, proof-of-concept Phase II study, the authors compared the efficacy of standard treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression among individuals at imminent suicide risk.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.